Document is current
Any future updates will be listed below
-
Authors
Tesfay, Betel https://orcid.org/0009-0006-3251-9052
Ashina, Håkan https://orcid.org/0000-0002-6268-727X
Karlsson, William Kristian https://orcid.org/0000-0003-0339-1417
Christensen, Rune Häckert https://orcid.org/0000-0002-3384-3579
Al-Khazali, Haidar M. https://orcid.org/0000-0001-7015-3369
Olsen, Dorte Aalund https://orcid.org/0000-0003-2589-738X
Madsen, Jonna Skov https://orcid.org/0000-0001-6668-4714
Ashina, Messoud https://orcid.org/0000-0003-0951-5804
-
Funding
Funding for this research was provided by:
Lundbeck Foundation (R310-2018–3711)
- License Information
-
More Information
Article History
Received: 6 July 2025
Accepted: 30 September 2025
First Online: 17 December 2025
Declarations
:
: The study protocol received approval from Scientific Ethics Committee for the Capital Region of Denmark. All procedures complied with the principles outlined in the Declaration of Helsinki, with later revisions.
: All participants provided written informed consent prior to enrollment.
: HA has received personal fees as a consultant or speaker from AbbVie, Lundbeck, Pfizer, and Teva, outside the submitted work. WKK has received personal fees as a speaker from Lundbeck and Pfizer, outside the submitted work. RHC has received personal fees as a speaker from Pfizer and Teva, outside the submitted work. HMA has received personal fees as a speaker from Pfizer, outside the submitted work. MA has received personal fees as a consultant or speaker from AbbVie, AstraZeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Pfizer, and Teva, outside the submitted work. The remaining authors declare no competing interests.
